Cargando…

Incidence of Antiphospholipid Syndrome: Is Estimation Currently Possible?

Antiphospholipid syndrome is a systemic autoimmune disorder characterized by vascular thrombosis and/or obstetric events in association with persistently elevated antiphospholipid antibodies. Antiphospholipid syndrome is typically considered a rare disease, but the true incidence is uncertain owing...

Descripción completa

Detalles Bibliográficos
Autores principales: Ioannou, Yiannis, Beukelman, Timothy, Murray, Miranda, Erkan, Doruk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mesut Onat 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10152079/
https://www.ncbi.nlm.nih.gov/pubmed/36880810
http://dx.doi.org/10.5152/eurjrheum.2023.22012
_version_ 1785035679686721536
author Ioannou, Yiannis
Beukelman, Timothy
Murray, Miranda
Erkan, Doruk
author_facet Ioannou, Yiannis
Beukelman, Timothy
Murray, Miranda
Erkan, Doruk
author_sort Ioannou, Yiannis
collection PubMed
description Antiphospholipid syndrome is a systemic autoimmune disorder characterized by vascular thrombosis and/or obstetric events in association with persistently elevated antiphospholipid antibodies. Antiphospholipid syndrome is typically considered a rare disease, but the true incidence is uncertain owing to the diverse antiphospholipid antibody-related clinical manifestations, inconsistent definitions of antiphospholipid antibody positivity, under-recognition of the disease, and limited population-based studies. Published estimates of the incidence of antiphospholipid syndrome range from approximately 2 to 80 per 100 000 person-years. A targeted literature review and applied methodology were performed to derive a best available estimate. Significant limitations of the published literature were observed, some of which have been previously reported. The incidence of antiphospholipid syndrome in the United States was estimated to be approximately 7.1 to 13.7 per 100 000 person-years in the general population. Although this estimate is likely more accurate than previously reported estimates, large, contemporary, population-based studies that reasonably adhere to the antiphospholipid syndrome classification criteria are needed to further refine estimates of the incidence of antiphospholipid syndrome.
format Online
Article
Text
id pubmed-10152079
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Mesut Onat
record_format MEDLINE/PubMed
spelling pubmed-101520792023-05-03 Incidence of Antiphospholipid Syndrome: Is Estimation Currently Possible? Ioannou, Yiannis Beukelman, Timothy Murray, Miranda Erkan, Doruk Eur J Rheumatol Literature Review Antiphospholipid syndrome is a systemic autoimmune disorder characterized by vascular thrombosis and/or obstetric events in association with persistently elevated antiphospholipid antibodies. Antiphospholipid syndrome is typically considered a rare disease, but the true incidence is uncertain owing to the diverse antiphospholipid antibody-related clinical manifestations, inconsistent definitions of antiphospholipid antibody positivity, under-recognition of the disease, and limited population-based studies. Published estimates of the incidence of antiphospholipid syndrome range from approximately 2 to 80 per 100 000 person-years. A targeted literature review and applied methodology were performed to derive a best available estimate. Significant limitations of the published literature were observed, some of which have been previously reported. The incidence of antiphospholipid syndrome in the United States was estimated to be approximately 7.1 to 13.7 per 100 000 person-years in the general population. Although this estimate is likely more accurate than previously reported estimates, large, contemporary, population-based studies that reasonably adhere to the antiphospholipid syndrome classification criteria are needed to further refine estimates of the incidence of antiphospholipid syndrome. Mesut Onat 2023-01-01 /pmc/articles/PMC10152079/ /pubmed/36880810 http://dx.doi.org/10.5152/eurjrheum.2023.22012 Text en 2023 authors https://creativecommons.org/licenses/by-nc/4.0/ Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. (https://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle Literature Review
Ioannou, Yiannis
Beukelman, Timothy
Murray, Miranda
Erkan, Doruk
Incidence of Antiphospholipid Syndrome: Is Estimation Currently Possible?
title Incidence of Antiphospholipid Syndrome: Is Estimation Currently Possible?
title_full Incidence of Antiphospholipid Syndrome: Is Estimation Currently Possible?
title_fullStr Incidence of Antiphospholipid Syndrome: Is Estimation Currently Possible?
title_full_unstemmed Incidence of Antiphospholipid Syndrome: Is Estimation Currently Possible?
title_short Incidence of Antiphospholipid Syndrome: Is Estimation Currently Possible?
title_sort incidence of antiphospholipid syndrome: is estimation currently possible?
topic Literature Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10152079/
https://www.ncbi.nlm.nih.gov/pubmed/36880810
http://dx.doi.org/10.5152/eurjrheum.2023.22012
work_keys_str_mv AT ioannouyiannis incidenceofantiphospholipidsyndromeisestimationcurrentlypossible
AT beukelmantimothy incidenceofantiphospholipidsyndromeisestimationcurrentlypossible
AT murraymiranda incidenceofantiphospholipidsyndromeisestimationcurrentlypossible
AT erkandoruk incidenceofantiphospholipidsyndromeisestimationcurrentlypossible